Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: chirodoc who wrote (2421)	7/2/1998 10:27:00 AM
From: Turboe	Respond to of 5402

AGREE!

To: chirodoc who wrote (2421)	7/2/1998 5:01:00 PM
From: Andrew H	Respond to of 5402

Here are a couple of other blood substitute companies: >>In December, the company made positive comments about its Phase III trial, the first in humans since BioTime had simply skipped the normal steps in moving from animal studies to human studies. Specifics released in mid-January revealed that Hextend had done as well as DuPont Merck's Hespan (the leading hetastarch product) but showed no significant new benefits. That was bad news since BioTime hoped to charge a lot more for Hextend and extend its use into other markets << Looks like BTIM has run into troubles of late and don't know anything about Hespan but with Dupont Merck behind it, it has power. There is also an SI thread for a company named Hemosol, which makes a similar product.